

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**HST: of sebelipase alfa for treating Wolman disease ID3995**

**Batch 83**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders raised that the population in this evaluation should include all people with lysosomal acid lipase (LAL) deficiency rather than focusing on Wolman disease. They stated that older children, adolescents and adults with LAL deficiency, may be negatively impacted by not having access to treatment with sebelipase alfa.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Later-onset LAL deficiency (cholesterol ester storage disease) is still being considered within the NICE evaluation of sebelipase alfa for treating LAL deficiency (ID737). It has been paused while this evaluation for treating Wolman disease is undertaken.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix

been made?
N/A

**Approved by Associate Director (name):** Richard. Diaz.....

**Date:** 24/02/22